Bausch Health Americas

According to the ClinicalTrials.gov registry, Bausch Health Americas is linked to 55 US clinical trials across every stage of research activity. Of those, 6 studies are currently recruiting — about 11% of the sponsor's indexed portfolio — and 44 are already marked complete, representing roughly 80% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Bausch Health Americas reports 32 late-stage studies (Phase 3 and Phase 4 combined) and 18 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Bausch Health Americas is Acne Vulgaris with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology — how this data is sourced, computed, and verified.

Browse all → | Rankings →

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Bausch Health Americas

Trial Pipeline

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

12-Week Study of Plecanatide for CIC (The CIC3 Study)

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Dose Ranging Study in Healthy Methadone Maintenance Subjects

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Open-Label Treatment Extension of Protocol MNTX 302

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

Tolerance and Pharmacokinetics Study of MNTX Tablets

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Compassionate Use Study of Methylnaltrexone

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Phase Distribution

Therapeutic Areas

What the Pipeline for Bausch Health Americas Shows

Related